PROGLYCEM SUSPENSION Rx
Generic Name and Formulations:
Diazoxide 50mg/mL; chocolate-mint flavor; contains alcohol 7.25%.
Indications for PROGLYCEM SUSPENSION:
Management of hypoglycemia due to hyperinsulinism associated with: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults; leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis in infants and children.
Adults and Children:
Individualize. Infants and newborns: Initially 10mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 8–15mg/kg divided into 2–3 equal doses every 8–12hrs. Adults and children: Initially 3mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 3–8mg/kg divided into 2–3 equal doses every 8–12hrs. Refractory hypoglycemia: may require higher dosages. Discontinue if not effective after 2–3 weeks.
Functional hypoglycemia. Thiazide hypersensitivity.
Compromised cardiac reserve: may precipitate CHF. Hyperuricemia. History of gout. Renal impairment: consider reducing dose; evaluate serum electrolyte levels. Newborns with increased bilirubinemia. Monitor for respiratory distress (esp. in those with risk factors); discontinue if pulmonary hypertension is suspected. Monitor blood glucose, BUN, creatinine clearance, hematocrit, platelets, total and differential leukocyte counts, AST, serum uric acid periodically until stabilized. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Nondiuretic benzothiadiazine derivative.
Antihypertensives potentiated. Concomitant coumarin: may need to reduce dose of anticoagulant. Concomitant diphenylhydantoin may result in loss of seizure control. Concomitant thiazides, other diuretics may potentiate hyperglycemic and hyperuricemic effects. Inhibits glucagon-stimulated insulin release and causes false-negative insulin response to glucagon.
Sodium and fluid retention, diabetic ketoacidosis, hyperosmolar nonketotic coma, hirsuitism, hyperglycemia, glycosuria, GI upset, tachycardia, palpitations, increased serum uric acid, thrombocytopenia (may require discontinuation), neutropenia, rash, headache, weakness, malaise.
Susp—30mL (w. dropper)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Symptoms of Anxiety, Depression Differ Depending on Gender, Race, Ethnicity
- Examining Whether Adjunctive Glutamatergic Medication Further Eases OCD Symptoms
- FDA Permits Marketing of Brain Stimulation Device for OCD
- Antipsychotics Adversely Affect Adiposity and Insulin Sensitivity in Youths
- Know Before You Go: Practicing Medicine Abroad